Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

October 17, 2023 updated by: Qiaofei Liu, Peking Union Medical College Hospital

Real World Status of Palliative Care for Pancreatic Cancer Patients in China-a National Multi-center Cross-sectional Survey

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Pancreatic cancer is a highly malignant gastrointestinal tumor with only a 10% overall 5-year survival rate. More than 80% of patients are already in the advanced stage when diagnosed, losing the chance of surgery. Advanced pancreatic cancer progresses rapidly and chemoradiotherapy has limited efficacy, so palliative care is thought to play an important role in the treatment process. However, due to the late development of palliative care, there is a lack of data on real-world clinical palliative care for pancreatic cancer patients in China.

This study investigates the real-world current status of palliative care for pancreatic cancer patients by sending a web questionnaire to the doctors from the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland. The survey aims to obtain the real status of palliative care and achieve a comprehensive understanding of how to develop palliative care in hospitals.

The questionnaire includes both subjective standards like the surgeons' opinion on the development of palliative therapy and objective standards such as dedicated beds and teams for palliative care.

Study Type

Observational

Enrollment (Estimated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100730
        • Recruiting
        • Peking Union Medical College Hospital
        • Contact:
          • Qiaofei Liu, MD
        • Principal Investigator:
          • Qiaofei Liu, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The doctors of the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland

Description

Inclusion Criteria:

  • Doctors from the General Surgery Department in Chinese public tertiary teaching hospitals and public primary care units
  • Approval to participate
  • Participants with a valid and complete questionnaire evaluated by 2 experienced surgeons

Exclusion Criteria:

  • Refusal to participate
  • Participants with an invalid or incomplete questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pancreatic cancer patients
Other: Observational study
Observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Descriptions and scores of real status of hospice care in different hospitals
Time Frame: 1 month
The primary outcome is objective standards and subjective scores of current status of palliative care to qutify the development of palliative care of different hospitals. The score is evaluated by a follow-up questionnaire. The maximum and minimum score is 10 and 0, respectively.
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Investigators

  • Study Chair: Qiaofei Liu, Department of General Surgery, Peking Union Medical College Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2025

Study Registration Dates

First Submitted

October 3, 2023

First Submitted That Met QC Criteria

October 17, 2023

First Posted (Actual)

October 19, 2023

Study Record Updates

Last Update Posted (Actual)

October 19, 2023

Last Update Submitted That Met QC Criteria

October 17, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • K4602

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe